Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Metastasis | Research

CHFR promotes metastasis of human gastric carcinoma by activating AKT and ERK via NRF2- ROS axis

Authors: Feiyun He, Bin Ye, Xiaomeng Wu, Jundi Pan, Jianbo Wang, Xiaojing Wang

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Tumor suppressor gene CHFR (The Checkpoint with Forkhead-associated and Ring finger domains) is a mitotic checkpoint and frequently hypermethylated in gastric cancer. Our previous study found CHFR played a certain extent pro-tumor function in gastric cancer. However, little is known about the underlying mechanism. In this study, we tried to further elucidate the role and mechanism for CHFR in gastric cancer (GC) by constructing CHFR stably expressed cell lines. As expected, the ectopic expression of CHFR slowed the cell proliferation in both two SGC-7901 and AGS cells, while significantly promoted the potential of cell migration and invasion. For the first time, our data indicated that stable expression of CHFR in SGC-7901 and AGS restrained cellular reactive oxygen species (ROS) generation and promoted the activation of AKT and ERK, two regulators of redox hemostasis. Furthermore, H2O2 treatment effectively elevated ROS level and reversed CHFR-induced cell invasion in stable SGC-7901 and AGS cells with the decreased phosphorylation of AKT and ERK. We also confirmed that CHFR exerted its function by promoting NRF2 expression. The most important is, the ectopic expression of CHFR significantly inhibited SGC-7901 cell-derived xenografts and obviously promoted lung metastasis of GC cell with NRF2, p-AKT and p-ERK increased. Taken together, our findings suggested that CHFR might take part in gastric cancer progression especially cancer metastasis by activating AKT and ERK via NRF2- ROS axis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Cancer J Clin. 2015;65:87–108.CrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Cancer J Clin. 2015;65:87–108.CrossRef
2.
go back to reference Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. Cancer J Clin. 2016;66:115–32.CrossRef Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. Cancer J Clin. 2016;66:115–32.CrossRef
3.
go back to reference (2020) Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 70:313. (2020) Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 70:313.
4.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J Clin. 2011;61:69–90.CrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J Clin. 2011;61:69–90.CrossRef
5.
go back to reference Kang D, Chen J, Wong J, Fang G. The checkpoint protein chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol. 2002;156:249–59.CrossRefPubMedPubMedCentral Kang D, Chen J, Wong J, Fang G. The checkpoint protein chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol. 2002;156:249–59.CrossRefPubMedPubMedCentral
6.
go back to reference Yu X, Minter-Dykhouse K, Malureanu L, et al. Chfr is required for tumor suppression and Aurora a regulation. Nat Genet. 2005;37:401–6.CrossRefPubMed Yu X, Minter-Dykhouse K, Malureanu L, et al. Chfr is required for tumor suppression and Aurora a regulation. Nat Genet. 2005;37:401–6.CrossRefPubMed
7.
go back to reference Kim JM, Cho EN, Kwon YE, Bae SJ, Kim M, Seol JH. CHFR functions as a ubiquitin ligase for HLTF to regulate its stability and functions. Biochem Biophys Res Commun. 2010;395:515–20.CrossRefPubMed Kim JM, Cho EN, Kwon YE, Bae SJ, Kim M, Seol JH. CHFR functions as a ubiquitin ligase for HLTF to regulate its stability and functions. Biochem Biophys Res Commun. 2010;395:515–20.CrossRefPubMed
8.
go back to reference Cha Y, Kim SY, Yeo HY, et al. Association of CHFR promoter methylation with treatment outcomes of Irinotecan-Based chemotherapy in metastatic colorectal Cancer. Neoplasia. 2019;21:146–55.CrossRefPubMed Cha Y, Kim SY, Yeo HY, et al. Association of CHFR promoter methylation with treatment outcomes of Irinotecan-Based chemotherapy in metastatic colorectal Cancer. Neoplasia. 2019;21:146–55.CrossRefPubMed
9.
go back to reference Shibata Y, Haruki N, Kuwabara Y, et al. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis. 2002;23:1695–9.CrossRefPubMed Shibata Y, Haruki N, Kuwabara Y, et al. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis. 2002;23:1695–9.CrossRefPubMed
10.
go back to reference Brodie SA, Li G, Brandes JC. Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in the Cancer Genome Atlas (TCGA) project. Respir Med. 2015;109:131–6.CrossRefPubMed Brodie SA, Li G, Brandes JC. Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in the Cancer Genome Atlas (TCGA) project. Respir Med. 2015;109:131–6.CrossRefPubMed
11.
go back to reference Dai D, Zhou B, Xu W, Jin H, Wang X. CHFR promoter hypermethylation is Associated with gastric Cancer and plays a protective role in gastric Cancer process. J Cancer. 2019;10:949–56.CrossRefPubMedPubMedCentral Dai D, Zhou B, Xu W, Jin H, Wang X. CHFR promoter hypermethylation is Associated with gastric Cancer and plays a protective role in gastric Cancer process. J Cancer. 2019;10:949–56.CrossRefPubMedPubMedCentral
12.
go back to reference Yang S, He F, Dai M, Pan J, Wang J, Ye B. CHFR promotes the migration of human gastric cancer cells by inducing epithelial-to-mesenchymal transition in a HDAC1-dependent manner. Onco Targets Ther. 2019;12:1075–84.CrossRefPubMedPubMedCentral Yang S, He F, Dai M, Pan J, Wang J, Ye B. CHFR promotes the migration of human gastric cancer cells by inducing epithelial-to-mesenchymal transition in a HDAC1-dependent manner. Onco Targets Ther. 2019;12:1075–84.CrossRefPubMedPubMedCentral
13.
go back to reference Lyons AB, Blake SJ, Doherty KV. Flow cytometric analysis of cell division by dilution of CFSE and related dyes. Curr Protoc Cytom Chap. 2013;9:9. 11 11–19 11 12. Lyons AB, Blake SJ, Doherty KV. Flow cytometric analysis of cell division by dilution of CFSE and related dyes. Curr Protoc Cytom Chap. 2013;9:9. 11 11–19 11 12.
14.
go back to reference Pijuan J, Barcelo C, Moreno DF, et al. In vitro cell Migration, Invasion, and adhesion assays: from cell imaging to Data Analysis. Front Cell Dev Biol. 2019;7:107.CrossRefPubMedPubMedCentral Pijuan J, Barcelo C, Moreno DF, et al. In vitro cell Migration, Invasion, and adhesion assays: from cell imaging to Data Analysis. Front Cell Dev Biol. 2019;7:107.CrossRefPubMedPubMedCentral
15.
go back to reference Shu S, Li Z, Liu L, et al. HPV16 E6-Activated OCT4 promotes cervical Cancer Progression by suppressing p53 expression via Co-Repressor NCOR1. Front Oncol. 2022;12:900856.CrossRefPubMedPubMedCentral Shu S, Li Z, Liu L, et al. HPV16 E6-Activated OCT4 promotes cervical Cancer Progression by suppressing p53 expression via Co-Repressor NCOR1. Front Oncol. 2022;12:900856.CrossRefPubMedPubMedCentral
18.
go back to reference Rezatabar S, Karimian A, Rameshknia V, et al. RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression. Journal of cellular physiology; 2019. Rezatabar S, Karimian A, Rameshknia V, et al. RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression. Journal of cellular physiology; 2019.
19.
go back to reference Senyuk V, Eskandari N, Jiang Y, et al. Compensatory expression of NRF2-dependent antioxidant genes is required to overcome the lethal effects of Kv11.1 activation in breast cancer cells and PDOs. Redox Biol. 2021;45:102030.CrossRefPubMedPubMedCentral Senyuk V, Eskandari N, Jiang Y, et al. Compensatory expression of NRF2-dependent antioxidant genes is required to overcome the lethal effects of Kv11.1 activation in breast cancer cells and PDOs. Redox Biol. 2021;45:102030.CrossRefPubMedPubMedCentral
20.
go back to reference Wang C, Ma W, Wei R, et al. Clinicopathological significance of CHFR methylation in non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:109732–9.CrossRefPubMedPubMedCentral Wang C, Ma W, Wei R, et al. Clinicopathological significance of CHFR methylation in non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:109732–9.CrossRefPubMedPubMedCentral
21.
go back to reference Ma K, Cao B, Guo M. The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma. Clin epigenetics. 2016;8:43.CrossRefPubMedPubMedCentral Ma K, Cao B, Guo M. The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma. Clin epigenetics. 2016;8:43.CrossRefPubMedPubMedCentral
22.
go back to reference Zhou JD, Zhang TJ, Li XX, et al. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia. J Cell Physiol. 2018;233:4707–14.CrossRefPubMed Zhou JD, Zhang TJ, Li XX, et al. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia. J Cell Physiol. 2018;233:4707–14.CrossRefPubMed
23.
go back to reference Gao L, Liu F, Zhang H, Sun J, Ma Y. CHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome. Genes Chromosomes Cancer. 2016;55:158–68.CrossRefPubMed Gao L, Liu F, Zhang H, Sun J, Ma Y. CHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome. Genes Chromosomes Cancer. 2016;55:158–68.CrossRefPubMed
25.
go back to reference Aggarwal V, Tuli HS, Varol A et al. (2019) Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. Biomolecules 9. Aggarwal V, Tuli HS, Varol A et al. (2019) Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. Biomolecules 9.
26.
go back to reference Sznarkowska A, Kostecka A, Meller K, Bielawski KP. Inhibition of cancer antioxidant defense by natural compounds. Oncotarget. 2017;8:15996–6016.CrossRefPubMed Sznarkowska A, Kostecka A, Meller K, Bielawski KP. Inhibition of cancer antioxidant defense by natural compounds. Oncotarget. 2017;8:15996–6016.CrossRefPubMed
27.
go back to reference Zhang J, Wang X, Vikash V et al. (2016) ROS and ROS-Mediated Cellular Signaling. Oxid Med Cell Longev 2016:4350965. Zhang J, Wang X, Vikash V et al. (2016) ROS and ROS-Mediated Cellular Signaling. Oxid Med Cell Longev 2016:4350965.
29.
go back to reference Li Y, Yang Y, Lu Y, et al. Predictive value of CHFR and MLH1 methylation in human gastric cancer. Gastric Cancer. 2015;18:280–7.CrossRefPubMed Li Y, Yang Y, Lu Y, et al. Predictive value of CHFR and MLH1 methylation in human gastric cancer. Gastric Cancer. 2015;18:280–7.CrossRefPubMed
Metadata
Title
CHFR promotes metastasis of human gastric carcinoma by activating AKT and ERK via NRF2- ROS axis
Authors
Feiyun He
Bin Ye
Xiaomeng Wu
Jundi Pan
Jianbo Wang
Xiaojing Wang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02724-4

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.